Home
Agilis Biotherapeutics

Agilis Biotherapeutics Market Share Analysis for June 2026

Industry: N/A

Domainagilisbio.com

Year Founded2013

Employees51 - 200

Annual Revenue$2M - $5M

Agilis Biotherapeutics

Agilis Biotherapeutics (including company regionals)

agilisbio.com

See more website traffic and engagement information

Agilis Biotherapeutics Revenue up to June 2026 is 2M - 5M

revenue generated by Agilis Biotherapeutics top domains

Agilis Biotherapeutics top domains revenue over 3 years

Revenue for Agilis Biotherapeutics top domains

agilisbio.com2M - 5M

See more with Sales Intelligence

Total visits to Agilis Biotherapeutics's top domains

Understand Agilis Biotherapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Agilis Biotherapeutics's top domains

Analyze Agilis Biotherapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Agilis Biotherapeutics's top domains

See how Agilis Biotherapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Agilis Biotherapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Agilis Biotherapeutics

These are the website technologies, by industry, used by Agilis Biotherapeutics top domains

Content Management System (3)

WordPress

Email Services (2)

GoDaddy Email

Recruitment (2)

IBM Kenexa

Audio Video Media (1)

YouTube

More Technologies

3

See all

News & Signals from Agilis Biotherapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPTC Therapeutics, Inc. acquired Agilisbio for $200M on Jul 26th '18.PTC (Nasdaq: PTCT) said it would pay $50 million in cash and $150 million in PTC stock to acquire Agilis.

NewsAgilisbio is developing AAV gene therapy vectors.Agilis and GTRI plan to develop and manufacture AAV gene therapy vectors through the joint venture.

NewsAgilisbio hired Anne Marie Conway as Vice President Clinical Operations on May 7th '17.Agilis Biotherapeutics, Inc. (Agilis), a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), announced today that the Company has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as Chief Commercial Officer, Kirsten Gruis, M.D. as Chief Medical Officer, and Anne Marie Conway, M.H.A, R.N., as Vice President Clinical Operations.